• Sterile facility capex: IPO proceeds were reallocated toward expanding oral solid capacity in India and Atlanta, while the Atlanta sterile-injection project remains budgeted at approximately ₹107 crore and is slated for commercialization in 12 to 18 months.
• US tariff positioning: Potential US tariffs on generic drugs are viewed neutrally due to existing dual-region manufacturing, with plans to add a 4th commercial line to the US plant within 12 to 15 months alongside expanding Indian capacity.
• Emerging market margins: Although emerging market EBITDA margins fell to 14% from 19%–20% in Q4 FY26, management expects full-year margins to recover to 18%–20% driven by a stronger second half and first-to-launch opportunities.
• Long-term growth guidance: The company is targeting ₹2,500 to ₹3,000 crore in revenue within 3 to 5 years, alongside expectations of 30% to 40% revenue growth and 60% profit growth in FY27.
• Pipeline and CDMO: Current assets include 58 approved ANDAs representing 187 strengths, 35 products awaiting launch (136 strengths), 39 products under R&D, and 37 signed CDMO/CMO molecules across 120 strengths.